Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update

Carisma Therapeutics, Inc. (NASDAQ:CARM) was the recipient of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 537,700 shares, a decline of 5.4% from the December 31st total of 568,400 shares. Approximately 2.5% of the company’s shares are sold short. Based on an average daily trading volume, of 252,500 shares, the short-interest ratio is currently 2.1 days.

Institutional Investors Weigh In On Carisma Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Carisma Therapeutics in the 2nd quarter worth $40,000. Wexford Capital LP raised its holdings in Carisma Therapeutics by 75.5% during the third quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after buying an additional 15,000 shares during the last quarter. Finally, Barclays PLC lifted its stake in shares of Carisma Therapeutics by 3,661,933.3% in the third quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after buying an additional 549,290 shares in the last quarter. Institutional investors and hedge funds own 44.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Robert W. Baird lowered Carisma Therapeutics from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $10.00 to $1.00 in a research note on Thursday, December 12th. EF Hutton Acquisition Co. I raised shares of Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. BTIG Research downgraded shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a research report on Monday, December 16th. Finally, D. Boral Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Carisma Therapeutics in a research report on Monday, January 13th. Five analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Carisma Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $4.94.

Carisma Therapeutics Stock Down 0.6 %

NASDAQ:CARM traded down $0.00 during trading hours on Monday, reaching $0.46. The company had a trading volume of 241,403 shares, compared to its average volume of 533,388. Carisma Therapeutics has a twelve month low of $0.38 and a twelve month high of $2.77. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 1.39. The firm has a market cap of $19.08 million, a price-to-earnings ratio of -0.29 and a beta of 1.56. The business’s 50-day simple moving average is $0.54 and its two-hundred day simple moving average is $0.84.

Carisma Therapeutics (NASDAQ:CARM) last issued its earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, meeting the consensus estimate of ($0.31). Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. The company had revenue of $3.39 million during the quarter. On average, equities analysts expect that Carisma Therapeutics will post -1.32 earnings per share for the current year.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.